Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has earned an average rating of "Buy" from the ten analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $21.4444.

Several research analysts have recently issued reports on TRVI shares. Needham & Company LLC decreased their price target on Trevi Therapeutics from $24.00 to $22.00 and set a "buy" rating for the company in a research note on Friday, August 8th. D. Boral Capital reiterated a "buy" rating and issued a $19.00 target price on shares of Trevi Therapeutics in a research report on Friday, November 14th. Morgan Stanley boosted their price target on shares of Trevi Therapeutics from $18.00 to $19.00 and gave the stock an "overweight" rating in a research report on Friday, November 14th. Raymond James Financial reduced their price target on shares of Trevi Therapeutics from $29.00 to $27.00 and set a "strong-buy" rating for the company in a research note on Friday, August 8th. Finally, B. Riley upgraded shares of Trevi Therapeutics to a "strong-buy" rating in a research note on Monday, November 17th.

Check Out Our Latest Report on Trevi Therapeutics

Institutional Trading of Trevi Therapeutics

Several institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its holdings in Trevi Therapeutics by 4.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,346 shares of the company's stock worth $195,000 after acquiring an additional 911 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in Trevi Therapeutics by 20.5% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company's stock valued at $70,000 after acquiring an additional 1,300 shares during the last quarter. Persistent Asset Partners Ltd boosted its position in shares of Trevi Therapeutics by 3.3% during the 2nd quarter. Persistent Asset Partners Ltd now owns 42,788 shares of the company's stock valued at $234,000 after purchasing an additional 1,384 shares in the last quarter. BIT Capital GmbH grew its stake in shares of Trevi Therapeutics by 32.0% in the 3rd quarter. BIT Capital GmbH now owns 6,739 shares of the company's stock worth $62,000 after purchasing an additional 1,633 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of Trevi Therapeutics by 2.1% in the 1st quarter. American Century Companies Inc. now owns 79,796 shares of the company's stock worth $502,000 after purchasing an additional 1,653 shares in the last quarter. Institutional investors and hedge funds own 95.76% of the company's stock.

Trevi Therapeutics Stock Performance

TRVI stock opened at $10.99 on Friday. The stock's fifty day moving average is $10.14 and its two-hundred day moving average is $7.99. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -29.70 and a beta of 0.67. Trevi Therapeutics has a 1 year low of $2.36 and a 1 year high of $12.30.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.02. As a group, analysts predict that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.

Featured Articles

• Five stocks we like better than Trevi Therapeutics
• TSX Venture Exchange (Formerly Canadian Venture Exchange)
• MP Materials Stock Soared After Earnings—Here’s the Real Reason
• How Can Investors Benefit From After-Hours Trading
• Why Palantir Slide May Be a Setup for a Long-Term Opportunity
• What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
• Attention Income Investors: This REIT Is on Sale

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Trevi Therapeutics Right Now?

Before you consider Trevi Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.

While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here